Joseph J Palamar1, Austin Le2, Honoria Guarino3, Pedro Mateu-Gelabert3. 1. Department of Population Health, NYU School of Medicine, New York, NY, USA; Center for Drug Use and HIV/HCV Research, NYU College of Global Public Health, 665 Broadway, New York, NY, USA. Electronic address: joseph.palamar@nyulangone.org. 2. Department of Population Health, NYU School of Medicine, New York, NY, USA; New York University College of Dentistry, 345 E. 24th Street, 1st Avenue, New York, NY, USA. 3. Center for Drug Use and HIV/HCV Research, NYU College of Global Public Health, 665 Broadway, New York, NY, USA; National Development and Research Institutes, 71 W 23rd St, New York, NY, USA.
Abstract
BACKGROUND: Biological testing can be used to validate or detect underreported drug use. Since hair testing is increasingly used in survey research, we examined how the utility of hair testing compares to a more common method-urine testing. METHODS: 532 adults (ages 18-29) reporting past-month heroin use and/or nonmedical prescription opioid use were surveyed about past-month use of various drugs. Participants were urine-tested and the majority (79.3%) provided a hair sample for analysis. We examined the utility of urine vs. hair-testing in detecting past-month use of various drugs. RESULTS: Compared to hair testing, urine testing was able to confirm higher proportions of self-reported use of heroin/opioids (85.5% vs. 80.9%), marijuana (73.9% vs. 22.9%), benzodiazepines (51.3% vs. 15.1%), and methadone (77.0% vs. 48.7%), while hair testing was more likely to detect reported cocaine use (66.3% vs. 48.0%) (Ps<.01). Compared to hair testing, urine testing was more likely to detect unreported use of marijuana (11.3% vs. 0.9%), and benzodiazepines (14.4% vs. 5.4%), and hair testing was more likely to detect unreported use of cocaine (27.0% vs. 5.8%) and oxycodone (19.7% vs. 1.4%) (Ps<.001). When added to urine testing, hair testing increased detection of reported and non-reported use of cocaine and oxycodone ranging from 14 to 22%. CONCLUSIONS: While hair testing is efficacious in detecting drug use in wide window periods (e.g., past-year use), it is less efficacious than urine testing when testing for past-month use of select drugs among opiate/opioid users. However, hair testing is particularly efficacious in detecting unreported use of cocaine and/or oxycodone.
BACKGROUND: Biological testing can be used to validate or detect underreported drug use. Since hair testing is increasingly used in survey research, we examined how the utility of hair testing compares to a more common method-urine testing. METHODS: 532 adults (ages 18-29) reporting past-month heroin use and/or nonmedical prescription opioid use were surveyed about past-month use of various drugs. Participants were urine-tested and the majority (79.3%) provided a hair sample for analysis. We examined the utility of urine vs. hair-testing in detecting past-month use of various drugs. RESULTS: Compared to hair testing, urine testing was able to confirm higher proportions of self-reported use of heroin/opioids (85.5% vs. 80.9%), marijuana (73.9% vs. 22.9%), benzodiazepines (51.3% vs. 15.1%), and methadone (77.0% vs. 48.7%), while hair testing was more likely to detect reported cocaine use (66.3% vs. 48.0%) (Ps<.01). Compared to hair testing, urine testing was more likely to detect unreported use of marijuana (11.3% vs. 0.9%), and benzodiazepines (14.4% vs. 5.4%), and hair testing was more likely to detect unreported use of cocaine (27.0% vs. 5.8%) and oxycodone (19.7% vs. 1.4%) (Ps<.001). When added to urine testing, hair testing increased detection of reported and non-reported use of cocaine and oxycodone ranging from 14 to 22%. CONCLUSIONS: While hair testing is efficacious in detecting drug use in wide window periods (e.g., past-year use), it is less efficacious than urine testing when testing for past-month use of select drugs among opiate/opioid users. However, hair testing is particularly efficacious in detecting unreported use of cocaine and/or oxycodone.
Authors: Emily R Grekin; Dace S Svikis; Phebe Lam; Veronica Connors; James M Lebreton; David L Streiner; Courtney Smith; Steven J Ondersma Journal: Psychol Addict Behav Date: 2010-12
Authors: Jan Gryczynski; Robert P Schwartz; Shannon Gwin Mitchell; Kevin E O'Grady; Steven J Ondersma Journal: Drug Alcohol Depend Date: 2014-05-17 Impact factor: 4.492
Authors: David M Ledgerwood; Bruce A Goldberger; Nathan K Risk; Collins E Lewis; Rumi Kato Price Journal: Addict Behav Date: 2008-05-08 Impact factor: 3.913
Authors: David L Olds; Harriet Kitzman; Elizabeth Anson; Joyce A Smith; Michael D Knudtson; Ted Miller; Robert Cole; Christian Hopfer; Gabriella Conti Journal: Pediatrics Date: 2019-11-20 Impact factor: 7.124
Authors: Natalie S Levy; Joseph J Palamar; Stephen J Mooney; Charles M Cleland; Katherine M Keyes Journal: Ann Epidemiol Date: 2022-01-03 Impact factor: 6.996